Schimmelpennink Evert B. 4
4 · LENZ Therapeutics, Inc. · Filed Mar 30, 2026
Research Summary
AI-generated summary of this filing
LENZ Therapeutics CEO Evert Schimmelpennink Buys Stock
What Happened Evert B. Schimmelpennink, President, CEO, Secretary and a director of LENZ Therapeutics, purchased 28,089 shares in an open-market transaction on 2026-03-27. The filing reports a weighted average price of $8.95 per share for a total reported value of $251,411. This transaction is coded P (purchase).
Key Details
- Transaction date: 2026-03-27; weighted average price reported as $8.95; total reported value $251,411.
- Footnote: purchases occurred in the price range $8.80 to $9.25; the reporting person offered to provide the exact number of shares bought at each price upon request.
- Shares owned after the transaction: not disclosed in the provided filing.
- Filing date (Form 4): 2026-03-30. No late-filing flag was indicated in the provided data.
Context This was a straight open-market purchase (code P). Purchases by a company’s CEO are factual data points that some investors view as a positive signal, but they do not, by themselves, explain the insider’s motivations. The footnote clarifies the reported $8.95 figure is a weighted average across multiple execution prices.
Insider Transaction Report
- Purchase
Common Stock
[F1]2026-03-27$8.95/sh+28,089$251,411→ 77,289 total
Footnotes (1)
- [F1]Represents the weighted average share price of an aggregate total of 28,089 shares purchased in the price range of $8.80 to $9.25 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.